CanSino’s Inhaled COVID Booster Gets the Go‑Signal in China
In a breezy Sunday announcement, China’s CanSino Biologics Inc revealed that its newly crafted inhaled adenovirus‑based COVID‑19 jab has secured emergency‑use approval from the National Medical Products Administration. This could mean a big lift for the company’s bottom line.
What the Approval Actually Means
CanSino highlighted that the green light will be a boon “if government bodies actually buy and deploy the vaccine.” However, the company is quick to note that it will have to tussle with a line of rivals—both approved boosters and those still in trials.
Other Players in China’s Booster Arena
- Livzon Pharmaceutical Group recently snagged emergency use status for its booster, giving China its first new official product in over a year.
- There are still other contenders in the mix, all vying for the country’s vaccination budgets.
Market Timing: The Unknowns
CanSino remains cautious about when the vaccine will actually hit shelves, citing the need for further regulatory green lights. Whether it flies off the plane depends on:
- The ongoing COVID situation at home and abroad.
- China’s current vaccination rates.
China’s Current COVID Buzz
Shenzhen’s tech hub rolled out a weekend lockdown Saturday, and Chengdu put a 21‑million‑strong metropolis under house‑bound rules Thursday. Mainland China logged 1,848 new cases on September 3 (symptomatic and asymptomatic combined), a slight dip from 1,988 the day before.
What’s Next for CanSino?
With a calm inside the policy corridors but a chaotic outbreak scene outside, CanSino’s inhaled booster sits at a crossroads: poised for great gains but also braced for stiff competition. Time will tell if this new delivery method becomes the go‑to choice for China’s fight against COVID‑19.
